E1	Eq-Comparison:T1 Value:T61 Operator:T2 Temporal-Unit:T90 Value2:T93 Temporal-Unit2:T91
E4	Procedure:T4 Name:T94
E5	Procedure:T5 Name:T95
E6	Modifier:T6 Modifies:T95
E8	Modifier:T8 Modifies:T95
E10	Procedure:T10 Name:T96
E11	Eq-Comparison:T11 Temporal-Period:T97
E12	Procedure:T12 Temporality:E11 Duration:E20 Temporality2:E21
E13	Drug:T13 Name:T98
E16	Drug:T16 Name:T99
E17	Drug:T17 Name:T100
E19	Modifier:T19 
E20	Eq-Comparison:T20 Operator:T102 Value:T103 Temporal-Unit:T104
E21	Eq-Comparison:T21 Temporal-Period:T105 Value:T106 Temporal-Unit:T107
E22	Modifier:T22 Modifies:T108
E23	Condition:T23 Name:T108
E24	Condition:T24 Name:T18 Stability:T109
E26	Negation:T26 Negates:E27
E27	Assertion:T27 Asserted:E28
E28	Observation:T101 Name:T92 Numeric-Filter:E29
E29	Eq-Comparison:T29 Operator:T110 Value:T111 Unit:T112
E31	Assertion:T31 Asserted:E32
E32	Drug:T32 Name:T114
E33	Assertion:T33 Asserted:E34
E34	Drug:T34 Name:T115
E35	Drug:T35 Name:T116
E37	Drug:T37 Name:T117 Duration:E39
E39	Eq-Comparison:T39 Operator:T118 Value:T119 Temporal-Unit:T120
E41	Condition:T41 Name:T122
E42	Assertion:T42 Asserted:E43
E43	Procedure:T43 
E44	Eq-Comparison:T44 Temporal-Period:T123
E45	Condition:T45 Name:T124 Temporality:E44
E47	Eq-Comparison:T47 Operator:T126 Value:T127 Temporal-Unit:T128
E52	Procedure:T52 Name:T49
E53	Eq-Comparison:T53 Temporal-Period:T130
E54	Modifier:T54 Modifies:T131
E55	Condition:T55 Name:T131 Temporality:E53
E56	Condition:T56 Name:T133 Stage:E57 Acuteness:T132
E57	Eq-Comparison:T57 Operator:T134 Unit:T135 Value:T136
E58	Assertion:T58 Asserted:E61
E60	Assertion:T60 Asserted:E88
E61	Procedure:T62 Name:T137
E62	Procedure:T63 Name:T138
E63	Eq-Comparison:T64 Temporal-Period:T139
E64	Procedure:T65 Temporality:E63 Temporality2:E67
E65	Study:T66 Study-Of:E66
E66	Drug:T67 
E67	Eq-Comparison:T68 Operator:T140 Value:T141 Temporal-Unit:T142
E69	Study:T70 
E70	Negation:T71 Negates:E71
E71	Procedure:T72 Name:T143
E72	Drug:T73 Name:T144
E74	Drug:T75 Name:T145
E75	Eq-Comparison:T76 Temporal-Period:T146
E76	Allergy:T77 Temporality:E75 Name:E79
E78	Condition:T79 Name:T147
E80	Modifier:T81 Modifies:E83
E82	Modifier:T83 Modifies:E83
E83	Condition:T84 
E84	Assertion:T85 Asserted:T148
E85	Study:T86 Stability:T148
E87	Risk:T88 
E88	Negation:T89 Negates:E61
E2	Modifier:T15 Modifies:T100
E15	Modifier:T30 Modifies:T92
E30	Modifier:T113 Modifies:T114
E89	Modifier:T150 Modifies:T115
E38	Modifier:T38 Modifies:T117
E91	Procedure:T152 Name:T121
E46	Organism:T46 Name:T125
E49	Procedure:T50 Name:T129
E50	Assertion:T153 Asserted:E70
E79	Coreference:T80 Refers-To:E74 Refers-To2:E72
T1	Eq-Comparison 42 65	day -10 pre- to day +30
T4	Procedure 71 111	allogeneic hematopoietic cell transplant
T5	Procedure 113 117	AHCT
T6	Modifier 128 133	donor
T8	Modifier 137 149	graft source
T10	Procedure 162 182	conditioning regimen
T11	Eq-Comparison 206 214	received
T12	Procedure 215 224	treatment
T13	Drug 230 239	meropenem
T16	Drug 243 266	piperacillin-tazobactam
T17	Drug 268 276	pip-tazo
T19	Modifier 293 295	IV
T20	Eq-Comparison 301 327	at least 24 hours duration
T21	Eq-Comparison 332 343	past 7 days
T22	Modifier 349 359	Controlled
T23	Condition 360 369	infection
T24	Condition 381 396	hemodynamically
T26	Negation 408 411	not
T27	Assertion 412 421	requiring
T29	Eq-Comparison 445 467	more than 2 liters via
T31	Assertion 504 511	able to
T32	Drug 517 533	oral medications
T33	Assertion 703 717	anticipated to
T34	Drug 751 762	antibiotics
T35	Drug 768 777	meropenem
T37	Drug 781 789	pip-tazo
T39	Eq-Comparison 797 807	> 96 hours
T41	Condition 855 865	infections
T42	Assertion 866 879	necessitating
T43	Procedure 890 899	treatment
T44	Eq-Comparison 921 926	prior
T45	Condition 938 947	infection
T47	Eq-Comparison 988 1007	greater than 2 days
T52	Procedure 1049 1053	AHCT
T53	Eq-Comparison 1073 1079	active
T54	Modifier 1080 1087	enteric
T55	Condition 1088 1098	infections
T56	Condition 1124 1128	GVHD
T57	Eq-Comparison 1129 1140	>= grade II
T58	Assertion 1155 1164	unwilling
T60	Assertion 1168 1174	unable
T62	Procedure 1190 1193	FMT
T63	Procedure 1198 1223	retention enema procedure
T64	Eq-Comparison 1247 1255	received
T65	Procedure 1256 1265	treatment
T66	Study 1274 1289	investigational
T67	Drug 1290 1295	agent
T68	Eq-Comparison 1296 1310	within 2 weeks
T70	Study 1314 1324	enrollment
T71	Negation 1339 1357	unable to tolerate
T72	Procedure 1358 1378	oral decontamination
T73	Drug 1390 1398	pip-tazo
T75	Drug 1403 1411	nystatin
T76	Eq-Comparison 1419 1424	prior
T77	Allergy 1425 1432	allergy
T79	Condition 1436 1447	intolerance
T81	Modifier 1492 1499	medical
T83	Modifier 1503 1516	psychological
T84	Condition 1517 1526	condition
T85	Assertion 1569 1574	might
T86	Study 1625 1630	trial
T88	Risk 1652 1656	risk
T89	Negation 1168 1174	unable
T90	Eq-Temporal-Unit 42 45	day
T91	Eq-Temporal-Unit 58 61	day
T93	Eq-Value 63 65	30
T94	Procedure-Name 71 111	allogeneic hematopoietic cell transplant
T95	Procedure-Name 113 117	AHCT
T96	Procedure-Name 162 182	conditioning regimen
T97	Eq-Temporal-Period 206 214	received
T98	Drug-Name 230 239	meropenem
T99	Drug-Name 243 266	piperacillin-tazobactam
T100	Drug-Name 268 276	pip-tazo
T102	Eq-Operator 301 309	at least
T103	Eq-Value 310 312	24
T104	Eq-Temporal-Unit 313 318	hours
T105	Eq-Temporal-Period 332 336	past
T106	Eq-Value 337 338	7
T107	Eq-Temporal-Unit 339 343	days
T108	Condition-Name 360 369	infection
T109	Stability 397 403	stable
T110	Eq-Operator 445 454	more than
T111	Eq-Value 455 456	2
T112	Eq-Unit 457 463	liters
T114	Drug-Name 517 533	oral medications
T115	Drug-Name 751 762	antibiotics
T116	Drug-Name 768 777	meropenem
T117	Drug-Name 781 789	pip-tazo
T118	Eq-Operator 797 798	>
T119	Eq-Value 799 801	96
T120	Eq-Temporal-Unit 802 807	hours
T121	Procedure-Name 813 824	engraftment
T122	Condition-Name 855 865	infections
T123	Eq-Temporal-Period 921 926	prior
T124	Condition-Name 938 947	infection
T126	Eq-Operator 988 1000	greater than
T127	Eq-Value 1001 1002	2
T128	Eq-Temporal-Unit 1003 1007	days
T130	Eq-Temporal-Period 1073 1079	active
T131	Condition-Name 1088 1098	infections
T132	Acuteness 1118 1123	acute
T133	Condition-Name 1124 1128	GVHD
T134	Eq-Operator 1129 1131	>=
T135	Eq-Unit 1132 1137	grade
T136	Eq-Value 1138 1140	II
T137	Procedure-Name 1190 1193	FMT
T138	Procedure-Name 1198 1223	retention enema procedure
T139	Eq-Temporal-Period 1247 1255	received
T140	Eq-Operator 1296 1302	within
T141	Eq-Value 1303 1304	2
T142	Eq-Temporal-Unit 1305 1310	weeks
T143	Procedure-Name 1358 1378	oral decontamination
T144	Drug-Name 1390 1398	pip-tazo
T145	Drug-Name 1403 1411	nystatin
T146	Eq-Temporal-Period 1419 1424	prior
T147	Condition-Name 1436 1447	intolerance
T148	Stability 1575 1584	interfere
T149	Stability 1677 1685	confound
T61	Eq-Value 46 49	-10
T2	Eq-Operator 55 57	to
T15	Modifier 278 291	intravenously
T18	Condition-Name 381 396	hemodynamically
T92	Observation-Name 422 441	supplemental oxygen
T30	Modifier 468 481	nasal cannula
T101	Observation 422 441	supplemental oxygen
T113	Modifier 537 552	suspension form
T150	Modifier 736 750	broad spectrum
T38	Modifier 790 792	IV
T152	Procedure 813 824	engraftment
T46	Organism 953 965	mycormycetes
T125	Organism-Name 953 965	mycormycetes
T49	Procedure-Name 1049 1053	AHCT
T50	Procedure 1021 1043	neutrophil engraftment
T129	Procedure-Name 1021 1043	neutrophil engraftment
T153	Assertion 1339 1357	unable to tolerate
T80	Coreference 1451 1468	these medications
A2	Assertion-Type-Value E27 hypothetical
A3	Assertion-Type-Value E31 hypothetical
A4	Assertion-Type-Value E33 hypothetical
A6	Assertion-Type-Value E42 hypothetical
A9	Assertion-Type-Value E58 hypothetical
A10	Assertion-Type-Value E60 hypothetical
A12	Assertion-Type-Value E84 hypothetical
A13	Eq-Temporal-Unit-Value T90 day
A14	Eq-Temporal-Unit-Value T91 day
A16	Eq-Temporal-Period-Value T97 past
A17	Eq-Operator-Value T102 GTEQ
A18	Eq-Temporal-Unit-Value T104 hour
A19	Eq-Temporal-Period-Value T105 past
A20	Eq-Temporal-Unit-Value T107 day
A21	Stability-Value T109 stable
A22	Eq-Operator-Value T110 GT
A23	Eq-Operator-Value T118 GT
A24	Eq-Temporal-Unit-Value T120 hour
A25	Eq-Temporal-Period-Value T123 past
A26	Eq-Operator-Value T126 GT
A27	Eq-Temporal-Unit-Value T128 day
A28	Eq-Temporal-Period-Value T130 present
A30	Eq-Operator-Value T134 GTEQ
A31	Eq-Temporal-Period-Value T139 past
A32	Eq-Operator-Value T140 LTEQ
A33	Eq-Temporal-Unit-Value T142 week
A34	Eq-Temporal-Period-Value T146 past
A35	Stability-Value T148 change
A36	Stability-Value T149 change
A15	Eq-Operator-Value T2 BETWEEN
A37	Assertion-Type-Value E50 hypothetical
A38	Acuteness-Type-Value T132 acute
R1	Abbrev-Of Arg1:E5 Arg2:E4
R2	Using Arg1:E12 Arg2:E13
R3	Abbrev-Of Arg1:E17 Arg2:E16
R4	Abbrev-Of Arg1:E19 Arg2:E2
R5	Using Arg1:E12 Arg2:E16
R6	Equivalent-To Arg1:E24 Arg2:E23
R7	Treatment-For Arg1:E43 Arg2:E41
R8	Treatment-For Arg1:E34 Arg2:E41
R9	Caused-By Arg1:E45 Arg2:E46
R10	Using Arg1:E61 Arg2:E62
R11	Using Arg1:E64 Arg2:E66
R12	Using Arg1:E71 Arg2:E72
R13	Caused-By Arg1:E78 Arg2:E79
R14	Caused-By Arg1:E70 Arg2:E76
R15	Caused-By Arg1:T148 Arg2:E83
R16	Caused-By Arg1:E87 Arg2:E83
R17	Caused-By Arg1:T149 Arg2:E83
R18	After Arg1:E1 Arg2:E4
R19	Or Arg1:E6 Arg2:E8
R20	And Arg1:E5 Arg2:E10
R21	Or Arg1:E13 Arg2:E16
R22	And Arg1:E26 Arg2:E24
R23	Or Arg1:E35 Arg2:E37
R24	After Arg1:E37 Arg2:E91
R25	After Arg1:E47 Arg2:E49
R26	After Arg1:E49 Arg2:E52
R27	Or Arg1:E58 Arg2:E60
R28	Before Arg1:E67 Arg2:E69
R29	Or Arg1:E72 Arg2:E74
R30	Or Arg1:E76 Arg2:E78
R31	Or Arg1:E80 Arg2:E82
R32	And Arg1:E34 Arg2:E35
R33	Or Arg1:E87 Arg2:T149
